Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

Find insight on Sartorius, China’s healthcare industry and more in the latest Market Talks covering health care.

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Copenhagen, Denmark, March 27, 2025-Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...

Roche tells Andrew McConaghie that inaccurate reports of its price have distorted the debate. Just as US pharma is once again mired in controversy following the uproar around Martin Shkreli's 5000 ...

US President Donald Trump has again singled out Ireland's pharmaceutical industry as a target for tariffs. Trump was speaking as he announced 25% tariffs on cars and car parts imported into the US.

Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a ...